CVS long-term care pharmacy pays $15 million penalty for failing to track opioids

first_img What is it? Pharmalot CVS long-term care pharmacy pays $15 million penalty for failing to track opioids STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. GET STARTED Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED What’s included? [email protected] Omnicare, which is the largest long-term care pharmacy in the U.S., agreed to pay a $15.3 million penalty for allegedly allowing opioids and other controlled substances to be dispensed without valid prescriptions.The CVS Health (CVS) unit failed to track limited stockpiles of the medicines that were stored in so-called emergency kits, which are supposed to be dispensed by long-term care facilities on an emergency basis, but only with valid prescriptions, according to the U.S. Drug Enforcement Administration. Omnicare also repeatedly failed to document and report emergency prescriptions. @Pharmalot center_img By Ed Silverman May 13, 2020 Reprints About the Author Reprints Log In | Learn More SAUL LOEB/AFP/Getty Images Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Ed Silverman Tags opioidsSTAT+last_img read more